[go: up one dir, main page]

CN102633819A - Preparation method of cefoxitin - Google Patents

Preparation method of cefoxitin Download PDF

Info

Publication number
CN102633819A
CN102633819A CN2012101220349A CN201210122034A CN102633819A CN 102633819 A CN102633819 A CN 102633819A CN 2012101220349 A CN2012101220349 A CN 2012101220349A CN 201210122034 A CN201210122034 A CN 201210122034A CN 102633819 A CN102633819 A CN 102633819A
Authority
CN
China
Prior art keywords
compound
acid
formula
add
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012101220349A
Other languages
Chinese (zh)
Inventor
许洪飞
史韶华
汤沸
王勇进
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qilu Anti Linyi Pharmaceutical Co ltd
Original Assignee
Qilu Anti Linyi Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qilu Anti Linyi Pharmaceutical Co ltd filed Critical Qilu Anti Linyi Pharmaceutical Co ltd
Priority to CN2012101220349A priority Critical patent/CN102633819A/en
Publication of CN102633819A publication Critical patent/CN102633819A/en
Pending legal-status Critical Current

Links

Landscapes

  • Cephalosporin Compounds (AREA)

Abstract

The invention relates to a preparation method of cefoxitin, which comprises the following steps: adding an organic solvent A into the compound aqueous solution with the structure of the formula (IV), adding N, N' -dibenzylethylenediamine diacetate or the aqueous solution thereof, and filtering to obtain an intermediate compound with the structure of the formula (III); adding a compound with an intermediate structure shown in formula (III) into acetone or tetrahydrofuran, adding chlorosulfonyl isocyanate for reaction, and hydrolyzing after the reaction is finished; then adding ethyl acetate, filtering, extracting, decoloring, salting out, and filtering to obtain an intermediate compound with a structure of formula (II); adding a compound with an intermediate structure shown in formula (II) into an organic solvent B, adding organic acid for dissolving, adding a methanol solution of sodium methoxide and tert-butyl hypochlorite for methoxylation reaction, adding sodium metabisulfite and acetic acid for neutralization after the reaction is finished, adding water for extraction, carrying out acid precipitation on a water phase, and filtering to obtain cefoxitin; the deacetylcephalothin exists in the form of sodium salt or amine salt all the time, so that condensation side reaction easily caused by low pH is avoided, and the product quality and yield can be better controlled.

Description

一种头孢西丁的制备方法A kind of preparation method of cefoxitin

技术领域 technical field

本发明涉及一种化合物的制备方法,具体涉及一种头孢西丁的制备方法,属于药物化学合成技术领域。The invention relates to a preparation method of a compound, in particular to a preparation method of cefoxitin, and belongs to the technical field of pharmaceutical chemical synthesis.

背景技术 Background technique

头孢西丁钠(Cefoxitin Sodium),化学名为:(6R,7S)-3-氨基甲酰基氧甲基-7α-甲氧基-8-氧代-7β-[2-(2-噻吩基)乙酰胺基]-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-羧酸钠,是由美国Merck公司研制的半合成头霉素类抗生素,属于第二代头孢类抗生素。头孢西丁钠对革兰阴性菌有较强的抗菌作用,抗菌谱包括大肠杆菌、肺炎杆菌、吲哚阳性的变形杆菌和沙雷氏菌、克雷白杆菌、流感杆菌、沙门菌、志贺菌等。对葡萄球菌和多种链球菌也有较好作用。临床上主要用于上述敏感菌所致的呼吸道感染、心内膜炎、腹膜炎、肾盂肾炎、尿路感染、败血症以及骨、关节、皮肤和软组织等感染。Cefoxitin Sodium, chemical name: (6R, 7S)-3-carbamoyloxymethyl-7α-methoxy-8-oxo-7β-[2-(2-thienyl) Sodium acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate is a semi-synthetic cephamycin antibiotic developed by Merck Company of the United States, belonging to the second Substitute cephalosporin antibiotics. Cefoxitin sodium has a strong antibacterial effect on Gram-negative bacteria, and its antibacterial spectrum includes Escherichia coli, Klebsiella pneumoniae, indole-positive Proteus and Serratia, Klebsiella, influenza bacillus, Salmonella, and Shigella wait. It also has a good effect on staphylococcus and various streptococci. Clinically, it is mainly used for respiratory tract infection, endocarditis, peritonitis, pyelonephritis, urinary tract infection, sepsis, bone, joint, skin and soft tissue infection caused by the above-mentioned sensitive bacteria.

随着β-内酰胺类抗生素的广泛应用甚至滥用,刺激了细菌产生β-内酰胺酶的能力,从而导致耐药性问题日趋严重。由于头孢西丁钠7α位的甲氧基存在,使其对β-内酰胺酶相对一般的头孢菌素具有相对较强的抵抗性,这一点也是头霉素类抗生素的共性。With the widespread use and even abuse of β-lactam antibiotics, the ability of bacteria to produce β-lactamase is stimulated, which leads to the increasingly serious problem of drug resistance. Due to the presence of the methoxyl group at the 7α position of cefoxitin sodium, it has relatively strong resistance to β-lactamase compared with common cephalosporins, which is also the commonality of cefoxitin antibiotics.

头孢西丁酸,也称头孢西丁,是头孢西丁钠的自由酸形式,其化学结构如下:Cefoxitin acid, also known as cefoxitin, is the free acid form of cefoxitin sodium, and its chemical structure is as follows:

Figure BDA0000156683150000011
Figure BDA0000156683150000011

目前公开文献报道头孢西丁的合成路线有很多,但实现工业化生产都存在一定的问题。例如:There are many synthetic routes of cefoxitin reported in open literature at present, but there are certain problems in realizing industrialized production. For example:

1)美国专利文献US 4297488:以头霉素C为原料,通过酰基交换反应引入噻吩乙酰基,然后经过脱保护基反应得到头孢西丁,该方法虽然路线简单,但是原料头霉素C发酵水平低,难以如头孢菌素C一样实现工业化生产,使得该路线成本过高。实际上目前市场上唯一工业化的头霉素母核只有7-MAC,全称为7β-氨基-7α-甲氧基-3-[(1-甲基-1H-四唑-5-基)硫甲基]-3-头孢烯-4-羧酸二苯甲酯。1) U.S. Patent Document US 4297488: Using cephamycin C as raw material, thiopheneacetyl group is introduced through acyl exchange reaction, and then cefoxitin is obtained through deprotection group reaction. Although the method is simple, the fermentation level of raw material cefamycin C Low, it is difficult to realize industrial production like cephalosporin C, which makes the cost of this route too high. In fact, the only industrialized cephamycin core on the market is only 7-MAC, the full name is 7β-amino-7α-methoxy-3-[(1-methyl-1H-tetrazol-5-yl)thiomethyl Base]-3-cephem-4-carboxylic acid benzhydryl ester.

2)WO2004083217:以头孢噻吩为原料,经甲氧化、水解和氨甲酰化而得到头孢西丁。该方法实用性强,是目前生产头孢西丁的首选方法。2) WO2004083217: using cephalothin as raw material, cefoxitin was obtained through methoxidation, hydrolysis and carbamylation. The method is highly practical and is currently the preferred method for producing cefoxitin.

3)欧洲专利文献EP 1748049:公布了以头孢噻吩为起始原料,一步制得头孢西丁的方法。该工艺除了最后一步结晶外,中间没有结晶纯化步骤,产品杂质基本无法控制,几乎不可能达到各国药典的质量标准。3) European patent document EP 1748049: announced the method of using cephalothin as starting material to prepare cefoxitin in one step. In addition to the last step of crystallization, there is no crystallization and purification step in the process, and the product impurities are basically uncontrollable, and it is almost impossible to meet the quality standards of various pharmacopoeias.

4)中国专利文献CN101007812:以7β-氨基-7α-甲氧基-3-[(1-甲基-1H-四唑-5-基)硫甲基]-3-头孢烯-4-羧酸为原料,经过酰化、水解、氨甲酰化反应得到产品。该文献中所述的“7-MAC”实际上是公认的7-MAC的自由酸形式,只能由7-MAC水解得到,意味着4位羧基必需先保护后脱保护,总体收率不占优势。4) Chinese patent document CN101007812: 7β-amino-7α-methoxy-3-[(1-methyl-1H-tetrazol-5-yl)thiomethyl]-3-cephem-4-carboxylic acid As a raw material, the product is obtained through acylation, hydrolysis, and carbamylation reactions. The "7-MAC" described in this document is actually the recognized free acid form of 7-MAC, which can only be obtained by hydrolysis of 7-MAC, which means that the 4-position carboxyl group must be protected first and then deprotected, and the overall yield does not account for Advantage.

5)中国专利CN 101613361:以去乙酰7ACA为原料,经酰化、氨甲酰化,最后上甲氧基得到头孢西丁。该方法中去乙酰基头孢噻吩以酸的形式分离,pH过低,结晶时会部分形成头孢噻吩内酯,影响质量和收率。并且下一步与CSI反应时,在酸性和无水条件下形成头孢噻吩内酯的副反应更加严重,产品质量和收率难以保障。下面是该副反应的反应式:5) Chinese patent CN 101613361: use deacetylated 7ACA as raw material, undergo acylation, carbamylation, and finally methoxyl to obtain cefoxitin. In this method, deacetyl cephalothin is separated in the form of acid, and if the pH is too low, cephalothin lactone will be partially formed during crystallization, which will affect the quality and yield. And when reacting with CSI in the next step, the side reaction of forming cephalothin lactone under acidic and anhydrous conditions is more serious, and the product quality and yield are difficult to guarantee. The following is the reaction formula of this side reaction:

Figure BDA0000156683150000021
Figure BDA0000156683150000021

现有经报道的文献都存在原料或工艺条件不适合放大生产,或者,产品质量和收率竞争力不足的问题。The existing reported literatures all have the problem that the raw materials or process conditions are not suitable for scale-up production, or the product quality and yield are not competitive enough.

发明内容 Contents of the invention

本发明针对现有工艺的不足,提供一种头孢西丁的制备方法。The invention provides a preparation method of cefoxitin aiming at the deficiencies of the existing technology.

术语解释:Explanation of terms:

半苄星盐:即该化合物为两分子的去乙酰基头孢噻吩酸与一分子的苄星(即N,N’-二苄基乙二胺)所组成;Semi-benzathine salt: that is, the compound is composed of two molecules of deacetyl cephalothinic acid and one molecule of benzathine (i.e., N, N'-dibenzylethylenediamine);

DBED:N,N’-二苄基乙二胺二醋酸盐的缩写,又称苄星二醋酸盐、醋酸苄星;DBED: Abbreviation for N, N'-dibenzylethylenediamine diacetate, also known as benzathine diacetate and benzathine acetate;

CSI:氯磺酰异氰酸酯的缩写;CSI: Abbreviation for chlorosulfonyl isocyanate;

本发明的技术方案如下:Technical scheme of the present invention is as follows:

一种头孢西丁的制备方法,合成路线如下:A preparation method of cefoxitin, the synthetic route is as follows:

Figure BDA0000156683150000022
Figure BDA0000156683150000022

式中,M+为Na+或Et3NH+In the formula, M + is Na + or Et 3 NH + ;

包括如下步骤:Including the following steps:

(1)向式(IV)结构的化合物水溶液中,加入有机溶剂A,控温10℃~50℃加入N,N’-二苄基乙二胺二醋酸盐(DBED)或N,N’-二苄基乙二胺二醋酸盐的水溶液,中间体式(III)结构的化合物析出,降温至0~10℃,过滤取沉淀,得到中间体式(III)结构的化合物;(1) Add organic solvent A to the aqueous solution of the compound of formula (IV), and add N, N'-dibenzylethylenediamine diacetate (DBED) or N, N' - an aqueous solution of dibenzylethylenediamine diacetate, the compound of the intermediate formula (III) is precipitated, the temperature is lowered to 0-10° C., and the precipitate is filtered to obtain the compound of the intermediate formula (III);

有机溶剂A为:二氯甲烷、氯仿之一或任意比的组合;Organic solvent A is: one of dichloromethane, chloroform or a combination of any ratio;

(2)将步骤(1)制得的中间体式(III)结构的化合物加入到丙酮或四氢呋喃中,控温-65℃~-20℃,加入氯磺酰异氰酸酯(CSI)进行氨甲酰化反应,然后加入水或者酸升温至-10℃~20℃进行水解;水解完成后加入乙酸乙酯,过滤去除苄星盐酸盐,滤液用氯化钠水溶液洗涤后,有机相加入碳酸氢钠水溶液将产物萃取到水相,脱色后加氯化钠盐析,过滤取沉淀,得中间体式(II)结构的化合物;(2) Add the compound of the intermediate formula (III) obtained in step (1) into acetone or tetrahydrofuran, control the temperature at -65°C to -20°C, and add chlorosulfonyl isocyanate (CSI) for carbamylation reaction , then add water or acid and heat up to -10°C to 20°C for hydrolysis; add ethyl acetate after hydrolysis, filter to remove benzathine hydrochloride, wash the filtrate with aqueous sodium chloride, add aqueous sodium bicarbonate to the organic phase The product is extracted into the water phase, after decolorization, sodium chloride is added for salting out, and the precipitate is collected by filtration to obtain a compound of the intermediate formula (II);

(3)将步骤(2)制得的中间体式(II)结构的化合物加入有机溶剂B中,在-80~0℃的条件下,加入有机酸使其形成去甲氧基头孢西丁酸的过饱和溶液,然后控温-95~-70℃加入甲醇钠的甲醇溶液和次氯酸叔丁酯进行甲氧化反应;甲氧化反应结束后,加入焦亚硫酸钠和醋酸中和,加水萃取,水相经酸析,过滤取沉淀,得式(I)化合物,即头孢西丁;(3) The compound of the intermediate formula (II) structure obtained in step (2) is added in the organic solvent B, and under the condition of -80~0°C, an organic acid is added to form demethoxycefoxitin acid Supersaturated solution, then add methanol solution of sodium methoxide and tert-butyl hypochlorite under temperature control at -95~-70°C for methoxidation reaction; after methoxidation reaction, add sodium metabisulfite and acetic acid for neutralization, add water for extraction, water After acid analysis, the precipitate is filtered to obtain the compound of formula (I), i.e. cefoxitin;

有机溶剂B选自二氯甲烷、四氢呋喃、甲醇之一或任意比的组合。The organic solvent B is selected from one of dichloromethane, tetrahydrofuran, methanol or a combination in any ratio.

所述步骤(1)中式(IV)结构的化合物为去乙酰基头孢噻吩钠(M+为Na+)或去乙酰基头孢噻吩三乙胺盐(M+为Et3NH+)。其合成方法可参考本领域公开文献中的类似描述制得,如:由头孢噻吩钠在甲醇/水混合液中以氢氧化钠水解得到,然后减压蒸馏去除甲醇(参见美国专利文献US7662955);由头孢噻吩钠在乙酰酯酶催化水解后得到(参见中国专利文献CN101555252);由2-噻吩乙酰氯在三乙胺催化下与去乙酰基7-ACA反应(参见中国专利文献CN101914105A),然后浓缩去除有机溶剂。The compound of the formula (IV) in the step (1) is deacetylcefalotin sodium (M + is Na + ) or deacetylcefalotin triethylamine salt (M + is Et 3 NH + ). Its synthesis method can be obtained by referring to the similar descriptions in the open documents in this field, for example: it is obtained by hydrolyzing cefalotin sodium with sodium hydroxide in a methanol/water mixture, and then distilling off methanol under reduced pressure (see US Patent Document US7662955); Obtained from cefalotin sodium after catalyzed hydrolysis by acetyl esterase (see Chinese patent document CN101555252); react 2-thiopheneacetyl chloride with deacetylated 7-ACA under the catalysis of triethylamine (see Chinese patent document CN101914105A), and then concentrate Remove organic solvents.

根据本发明优选的,所述步骤(1)中式(IV)结构的化合物与N,N’-二苄基乙二胺二醋酸盐的反应摩尔比为1∶(0.5~1)。Preferably according to the present invention, the reaction molar ratio of the compound of formula (IV) and N,N'-dibenzylethylenediamine diacetate in the step (1) is 1: (0.5-1).

根据本发明优选的,所述步骤(1)中的有机溶剂A为二氯甲烷或氯仿。Preferably according to the present invention, the organic solvent A in the step (1) is dichloromethane or chloroform.

根据本发明优选的,所述步骤(2)中氯磺酰异氰酸酯与中间体式(III)结构的化合物摩尔比为(1~3)∶1。Preferably according to the present invention, the molar ratio of chlorosulfonyl isocyanate to the intermediate compound of formula (III) in the step (2) is (1-3):1.

根据本发明优选的,所述步骤(2)中,水解反应用酸为盐酸或硫酸。Preferably according to the present invention, in the step (2), the acid used for the hydrolysis reaction is hydrochloric acid or sulfuric acid.

根据本发明优选的,所述步骤(3)中的有机溶剂B为二氯甲烷或四氢呋喃,或者二氯甲烷、四氢呋喃与甲醇以任意比的组合;Preferably according to the present invention, the organic solvent B in the step (3) is dichloromethane or tetrahydrofuran, or a combination of dichloromethane, tetrahydrofuran and methanol in any ratio;

根据本发明优选的,所述步骤(3)中,所述有机酸为甲酸、三氟乙酸、氟硼酸、甲磺酸、对甲基苯磺酸之一或任意比的组合;优选的有机酸为甲磺酸或对甲基苯磺酸。Preferably according to the present invention, in the step (3), the organic acid is one of formic acid, trifluoroacetic acid, fluoroboric acid, methanesulfonic acid, p-toluenesulfonic acid or a combination of any ratio; preferred organic acid For methanesulfonic acid or p-toluenesulfonic acid.

根据本发明优选的,所述步骤(3)中,有机酸与中间体式(II)结构的化合物的摩尔比为(1~2)∶1。Preferably according to the present invention, in the step (3), the molar ratio of the organic acid to the compound of the intermediate formula (II) is (1-2):1.

根据本发明优选的,所述步骤(3)中,甲氧化反应温度为-95~-80℃,甲醇钠与中间体式(II)结构的化合物摩尔比为(3~8)∶1;次氯酸叔丁酯与中间体式(II)结构的化合物摩尔比为(1~3)∶1。Preferably according to the present invention, in the step (3), the methoxidation reaction temperature is -95 to -80°C, and the molar ratio of sodium methoxide to the compound of the intermediate formula (II) is (3 to 8): 1; The molar ratio of tert-butyl acid to the intermediate compound of formula (II) is (1-3):1.

根据本发明,优选的方案之一,一种头孢西丁的制备方法,包括如下步骤:According to the present invention, one of preferred schemes, a kind of preparation method of cefoxitin, comprises the steps:

(1)向含去乙酰基头孢噻吩钠100~120g的水溶液1000ml中加入200ml二氯甲烷(有机溶剂A),然后再控温20℃~40℃加入50~80g N,N’-二苄基乙二胺二醋酸盐与800ml水配成的溶液,中间体式(III)结构的化合物析出,降温至0~10℃,过滤取沉淀,得到中间体式(III)结构的化合物;(1) Add 200ml of dichloromethane (organic solvent A) to 1000ml of an aqueous solution containing 100-120g of deacetylcefalotin sodium, and then add 50-80g of N,N'-dibenzyl In a solution prepared from ethylenediamine diacetate and 800ml of water, the compound of the intermediate formula (III) is precipitated, the temperature is lowered to 0-10°C, and the precipitate is filtered to obtain the compound of the intermediate formula (III);

(2)将步骤(1)制得的中间体式(III)结构的化合物加入到1000ml丙酮中,降温至-50℃~-20℃滴加氯磺酰异氰酸酯35~60ml,进行氨甲酰化反应;HPLC检测氨甲酰化反应完成后,加入198ml水,升温至-10~10℃进行水解;水解完成后加入乙酸乙酯1980ml,过滤去除苄星盐酸盐,滤液用氯化钠水溶液洗涤,分层,有机相加入碳酸氢钠水溶液将产物萃取到水相,然后水相加入活性炭脱色,过滤,滤液加入200g的氯化钠盐析,中间体式(II)结构的化合物析出,搅拌1小时过滤,得到中间体式(II)结构的化合物;(2) Add the compound of intermediate formula (III) obtained in step (1) into 1000ml of acetone, cool down to -50°C to -20°C, and add 35 to 60ml of chlorosulfonyl isocyanate dropwise to carry out the carbamylation reaction ; After the carbamylation reaction was detected by HPLC, 198ml of water was added, and the temperature was raised to -10~10°C for hydrolysis; after the hydrolysis was completed, 1980ml of ethyl acetate was added, and benzathine hydrochloride was removed by filtration, and the filtrate was washed with aqueous sodium chloride solution. Layering, add aqueous sodium bicarbonate solution to the organic phase to extract the product into the water phase, then add activated carbon to the water phase for decolorization, filter, add 200g of sodium chloride to the filtrate for salting out, the compound of the intermediate formula (II) structure is precipitated, stir for 1 hour and filter , to obtain the compound of intermediate formula (II) structure;

(3)将步骤(2)制得的中间体式(II)结构的化合物加入到680ml四氢呋喃中,降温至-50~-10℃,加入16.0~21.4ml甲磺酸,降温至-95~-80℃,然后加入160~220g 30wt%甲醇钠的甲醇溶液和24.25~30.75g次氯酸叔丁酯进行甲氧化反应,反应完成后加入51g焦亚硫酸钠和61.5ml冰醋酸,然后加入活性炭脱色,再加入850ml水,用盐酸调节pH=2,降温至0~10℃,过滤取沉淀,得到式(I)结构的化合物,即头孢西丁。(3) Add the compound of intermediate formula (II) obtained in step (2) into 680ml of tetrahydrofuran, cool down to -50~-10°C, add 16.0~21.4ml of methanesulfonic acid, cool down to -95~-80°C ℃, then add 160-220g of 30wt% methanol solution of sodium methoxide and 24.25-30.75g of tert-butyl hypochlorite for methoxidation reaction, after the reaction is completed, add 51g of sodium metabisulfite and 61.5ml of glacial acetic acid, then add activated carbon for decolorization, and then add 850ml of water, adjusted to pH=2 with hydrochloric acid, cooled to 0-10°C, filtered to collect the precipitate, to obtain the compound of formula (I), ie cefoxitin.

本发明的技术特点:Technical characteristics of the present invention:

本发明步骤(1)中优选的有机溶剂能有效改善反应物的结晶过程。本发明步骤(2)中制备的中间体式(II)结构的化合物为钠盐,钠盐的形式有利于在下一步的甲氧化反应前低温酸化溶解形成过饱和溶液。若是如CN 101613361中分离出来的是去甲氧基头孢西丁酸,则下一步使用时几乎不可能溶解,加入有机碱或硅烷化都无法解决这一问题,后续的甲氧化反应在非均相条件下基本不能进行。The preferred organic solvent in the step (1) of the present invention can effectively improve the crystallization process of the reactants. The compound of the intermediate formula (II) prepared in the step (2) of the present invention is a sodium salt, and the form of the sodium salt is conducive to low-temperature acidification and dissolution before the next step of the methoxidation reaction to form a supersaturated solution. If it is demethoxycefoxitin acid isolated as in CN 101613361, it is almost impossible to dissolve in the next step of use, and adding organic base or silanization cannot solve this problem, and the follow-up methoxylation reaction is in the heterogeneous phase basically impossible under these conditions.

本发明有益效果如下:The beneficial effects of the present invention are as follows:

1、本发明中去乙酰基头孢噻吩以钠盐或胺盐的形式存在,避免了低pH容易导致的缩合副反应,克服了CN 101613361的弊端,能够较好的控制产品质量和收率,适应工业化生产。1. In the present invention, deacetylated cephalothin exists in the form of sodium salt or amine salt, which avoids the condensation side reaction easily caused by low pH, overcomes the disadvantages of CN 101613361, can better control product quality and yield, and adapts to Industrial production.

2、本发明向式(IV)结构的化合物的水溶液中加入有机溶剂A,能有效改善结晶过程,使用乙酸乙酯或其他溶剂都难以避免式(III)结构的化合物结晶析出时发泡严重的现象;2. The present invention adds organic solvent A to the aqueous solution of the compound of formula (IV) structure, which can effectively improve the crystallization process. It is difficult to avoid severe foaming when the compound of formula (III) structure crystallizes out using ethyl acetate or other solvents. Phenomenon;

3、本发明中式(II)结构的化合物为钠盐形式,克服了以酸的形式结晶后下一步使用时难以溶解的弊端,有利于产品溶解及进一步反应的进行。3. The compound of formula (II) in the present invention is in the form of sodium salt, which overcomes the disadvantage of being difficult to dissolve in the next step after crystallization in the form of acid, and is beneficial to product dissolution and further reaction.

4、本发明原料均为市场上惯常使用的物料,具有经济和三废易处理的优势,有效降低了头孢西丁酸合成的原料成本;并且综合收率高,产品质量容易控制,生产安全性高,适宜于大规模工业化生产。4. The raw materials of the present invention are commonly used materials in the market, and have the advantages of economy and easy disposal of three wastes, effectively reducing the cost of raw materials for the synthesis of cefoxitin acid; and the comprehensive yield is high, the product quality is easy to control, and the production safety is high. , suitable for large-scale industrial production.

具体实施方式 Detailed ways

下面结合实施例对本发明做进一步阐述,但本发明所保护范围不限于此。The present invention will be further described below in conjunction with the examples, but the protection scope of the present invention is not limited thereto.

实施例中所述去乙酰基头孢噻吩钠由头孢噻吩钠在乙酰酯酶催化水解后得到;头孢噻吩钠的制备方法按中国专利文献CN101555252(申请号200910027790.1)中实施例1制得的头孢噻吩酸用碳酸氢钠溶液溶解后得到;The deacetylated cephalothin sodium described in the examples is obtained by cefalotin sodium after catalyzed hydrolysis by acetyl esterase; the preparation method of cefalotin sodium is according to the cephalothin acid obtained in Example 1 in Chinese patent document CN101555252 (application number 200910027790.1). Obtained after dissolving with sodium bicarbonate solution;

次氯酸叔丁酯的制备方法参照《新型橡胶氯化剂的合成与表征》(李艳丽、石淑先等,北京化工大学学报,31(4):45~49)中的合成方法合成;The preparation method of tert-butyl hypochlorite is synthesized with reference to the synthetic method in "Synthesis and Characterization of New Rubber Chlorinating Agent" (Li Yanli, Shi Shuxian, etc., Journal of Beijing University of Chemical Technology, 31(4):45~49);

N,N’-二苄基乙二胺二醋酸盐购自上海国药集团试剂公司,氯磺酰异氰酸酯购自上海邦成化工公司,甲磺酸购自上海国药集团试剂公司。N, N'-dibenzylethylenediamine diacetate was purchased from Shanghai Sinopharm Group Reagent Company, chlorosulfonyl isocyanate was purchased from Shanghai Bangcheng Chemical Company, and methanesulfonic acid was purchased from Shanghai Sinopharm Group Reagent Company.

实施例1Example 1

一种头孢西丁的制备方法,包括如下步骤:A preparation method of cefoxitin, comprising the steps of:

(1)向式(IV)结构的化合物的水溶液1000ml(含去乙酰基头孢噻吩钠110g)中加入200ml二氯甲烷(有机溶剂A),然后再控温30℃加入56g N,N’-二苄基乙二胺二醋酸盐与800ml水配成的溶液,中间体式(III)结构的化合物析出,降温至0~10℃搅拌2小时;过滤取沉淀,依次用水和二氯甲烷洗涤产品,真空干燥得到132g中间体式(III)结构的化合物,收率95.2%;(1) Add 200ml of dichloromethane (organic solvent A) to the aqueous solution 1000ml of the compound of formula (IV) structure (containing deacetyl cephalothin sodium 110g), then add 56g of N,N'-dichloromethane at 30°C with temperature control A solution made of benzylethylenediamine diacetate and 800ml of water, the compound of the intermediate formula (III) is precipitated, the temperature is lowered to 0-10°C and stirred for 2 hours; the precipitate is collected by filtration, and the product is washed with water and methylene chloride in turn, Vacuum drying gave 132g of the intermediate compound of formula (III), with a yield of 95.2%;

1H NMR(400MHz,CDCl3)检测,结果如下:Detected by 1 H NMR (400MHz, CDCl 3 ), the results are as follows:

1H NMR(400MHz,CDCl3)δ9.02(d,1H,J=8.4Hz,CONH),7.31-7.44(m,6H),6.92-6.96(m,2H,thiophene-H),7.73(br,2H,CONH2),5.53-5.56(dd,1H),4.95(d,1H,J=4.8),4.06-4.23(abd,2H,J=12.8Hz),3.92(s,2H),3.80(s,2H),3.39-3.54(abd,2H,J=18.0Hz),2.91(s,2H)。 1 H NMR (400MHz, CDCl 3 ) δ9.02 (d, 1H, J=8.4Hz, CONH), 7.31-7.44 (m, 6H), 6.92-6.96 (m, 2H, thiophene-H), 7.73 (br , 2H, CONH 2 ), 5.53-5.56(dd, 1H), 4.95(d, 1H, J=4.8), 4.06-4.23(abd, 2H, J=12.8Hz), 3.92(s, 2H), 3.80( s, 2H), 3.39-3.54 (abd, 2H, J = 18.0 Hz), 2.91 (s, 2H).

(2)将步骤(1)制得的中间体式(III)结构的化合物加入到1000ml丙酮中,降温至-40℃滴加氯磺酰异氰酸酯61ml,进行氨甲酰化反应;HPLC检测氨甲酰化反应完成后,加入198ml水,升温至-10℃进行水解反应;水解完成后加入乙酸乙酯1980ml,过滤去除苄星盐酸盐。滤液用氯化钠水溶液洗涤,分层。有机相加入碳酸氢钠水溶液将产物萃取到水相。水相加入活性炭脱色,过滤,滤液加入200g的氯化钠盐析,中间体式(II)结构的化合物析出,搅拌1小时;过滤取沉淀,然后用450ml丙酮和100ml纯化水的混合液洗涤产品,真空干燥得到102.3g中间体式(II)结构的化合物,收率87.7%;(2) Add the compound of the intermediate formula (III) structure obtained in step (1) to 1000ml of acetone, drop the temperature to -40°C and add 61ml of chlorosulfonyl isocyanate dropwise to carry out carbamylation reaction; HPLC detects carbamoyl After the completion of the chemical reaction, add 198ml of water, and heat up to -10°C to carry out the hydrolysis reaction; after the completion of the hydrolysis, add 1980ml of ethyl acetate, and filter to remove benzathine hydrochloride. The filtrate was washed with aqueous sodium chloride, and the layers were separated. An aqueous solution of sodium bicarbonate was added to the organic phase to extract the product into the aqueous phase. Add active carbon to the water phase for decolorization, filter, add 200g of sodium chloride to the filtrate for salting out, the compound of the intermediate formula (II) structure is separated out, stir for 1 hour; filter to get the precipitate, then wash the product with a mixed solution of 450ml acetone and 100ml purified water, Vacuum drying gave 102.3g of the intermediate compound of formula (II), with a yield of 87.7%;

1H NMR(400MHz,CDCl3)检测,结果如下:Detected by 1 H NMR (400MHz, CDCl 3 ), the results are as follows:

1H NMR(400MHz,CDCl3)δ9.02(d,1H,J=8.4Hz,CONH),7.34-7.36(m,1H,thiophene-H),,6.92-6.96(m,2H,thiophene-H),6.53(br,2H,CONH2),5.49(dd,1H,J=4.8,8.4Hz,lactom ring NCOCH-),4.95(d,1H,J=4.8Hz lactam ring-CHNS),4.74-4.88(abd,2H,J=12.0Hz),3.76-3.77(d,2H,J=2.4Hz),3.20-3.46(abd,2H,J=17.2Hz)。 1 H NMR (400MHz, CDCl 3 ) δ9.02 (d, 1H, J=8.4Hz, CONH), 7.34-7.36 (m, 1H, thiophene-H), 6.92-6.96 (m, 2H, thiophene-H ), 6.53 (br, 2H, CONH 2 ), 5.49 (dd, 1H, J=4.8, 8.4Hz, lactom ring NCOCH-), 4.95 (d, 1H, J=4.8Hz lactam ring-CHNS), 4.74-4.88 (abd, 2H, J=12.0 Hz), 3.76-3.77 (d, 2H, J=2.4 Hz), 3.20-3.46 (abd, 2H, J=17.2 Hz).

(3)将步骤(2)制得的中间体式(II)结构的化合物加入到680ml四氢呋喃(有机溶剂B)中,降温至-25℃,缓慢加入17.4ml甲磺酸;继续降温至-80℃,然后加入180g 30wt%甲醇钠的甲醇溶液和27.95g次氯酸叔丁酯进行甲氧化反应,反应完成后加入51g焦亚硫酸钠和61.5ml冰醋酸,然后加入活性炭脱色,再加入850ml水,用盐酸调节pH=2,式(I)结构的化合物析出,降温至0~10℃搅拌1小时;过滤取沉淀,用175ml纯化水和34ml四氢呋喃的混合液洗涤产品。真空干燥得到85.6g式(I)结构的化合物,即头孢西丁,收率82.1%;(3) Add the intermediate compound of formula (II) obtained in step (2) into 680ml of tetrahydrofuran (organic solvent B), cool down to -25°C, slowly add 17.4ml of methanesulfonic acid; continue to cool down to -80°C , then add 180g of 30wt% methanol solution of sodium methoxide and 27.95g of tert-butyl hypochlorite for methoxidation reaction, add 51g of sodium metabisulfite and 61.5ml of glacial acetic acid after the reaction is completed, then add activated carbon for decolorization, then add 850ml of water, and use hydrochloric acid Adjust the pH to 2, the compound of formula (I) is precipitated, lower the temperature to 0-10°C and stir for 1 hour; filter to collect the precipitate, and wash the product with a mixture of 175ml purified water and 34ml tetrahydrofuran. Vacuum drying obtained 85.6g of the compound of formula (I), i.e. cefoxitin, with a yield of 82.1%;

1H NMR(400MHz,CDCl3)检测,结果如下:Detected by 1 H NMR (400MHz, CDCl 3 ), the results are as follows:

1H NMR(400MHz,CDCl3)δ9.44(S,1H,CONH),7.36-7.37(m,1H,thiophene-H),6.95-6.97(m,2H,thiophene-H),6.59(br,2H,CONH2),5.15(s,1H,lactam ring-H),4.82(abd,1H,J=12.8Hz),4.60(abd,1H,J=12.8Hz),3.80-3.86(m,2H),3.54(abd,1H,J=18.0Hz),3.38(s,3H,OCH3),3.30(abd,1H,J=18.0Hz)。 1 H NMR (400MHz, CDCl 3 ) δ9.44 (S, 1H, CONH), 7.36-7.37 (m, 1H, thiophene-H), 6.95-6.97 (m, 2H, thiophene-H), 6.59 (br, 2H, CONH 2 ), 5.15(s, 1H, lactam ring-H), 4.82(abd, 1H, J=12.8Hz), 4.60(abd, 1H, J=12.8Hz), 3.80-3.86(m, 2H) , 3.54 (abd, 1H, J=18.0 Hz), 3.38 (s, 3H, OCH3), 3.30 (abd, 1H, J=18.0 Hz).

实施例2Example 2

如实施例1所述的头孢西丁的制备方法,不同之处在于:The preparation method of cefoxitin as described in embodiment 1, difference is:

步骤(1)中所述的有机溶剂A为氯仿,制得128.5g中间体式(III)结构的化合物,收率94.9%。The organic solvent A described in the step (1) is chloroform, and 128.5 g of the compound of the intermediate formula (III) is obtained, with a yield of 94.9%.

中间体式(III)结构的化合物经1H NMR(400MHz,CDCl3)检测,结果同实施例1。The intermediate compound of formula (III) was detected by 1 H NMR (400 MHz, CDCl 3 ), and the result was the same as that in Example 1.

实施例3Example 3

如实施例1所述的头孢西丁的制备方法,不同之处在于:The preparation method of cefoxitin as described in embodiment 1, difference is:

步骤(2)中将80g按照实施例1步骤(1)制得的中间体式(III)结构的化合物加入到600ml四氢呋喃中,降温至-50℃滴加氯磺酰异氰酸酯39ml,进行氨甲酰化反应;HPLC检测氨甲酰化反应完成后,加入120ml 5wt%盐酸,升温至10℃进行水解反应;水解完成后加入乙酸乙酯1200ml,然后过滤去除苄星盐酸盐。滤液用氯化钠水溶液洗涤,分层。有机相加入碳酸氢钠水溶液将产物萃取到水相。水相加入活性炭脱色,过滤,滤液加入120g的氯化钠盐析,中间体式(II)结构的化合物析出,搅拌1小时;过滤取沉淀,用300ml丙酮和50ml纯化水的混合液洗涤产品,真空干燥得到58.5g中间体式(II)结构的化合物,收率82.7%;In step (2), add 80 g of the compound of the intermediate formula (III) prepared according to step (1) of Example 1 into 600 ml of tetrahydrofuran, drop the temperature to -50°C and add 39 ml of chlorosulfonyl isocyanate dropwise for carbamylation Reaction: After the carbamylation reaction was detected by HPLC, 120ml of 5wt% hydrochloric acid was added, and the temperature was raised to 10°C for a hydrolysis reaction; after the hydrolysis was completed, 1200ml of ethyl acetate was added, and then benzathine hydrochloride was removed by filtration. The filtrate was washed with aqueous sodium chloride, and the layers were separated. An aqueous solution of sodium bicarbonate was added to the organic phase to extract the product into the aqueous phase. Add active carbon to the water phase for decolorization, filter, add 120g of sodium chloride to the filtrate for salting out, the compound of the intermediate formula (II) structure is precipitated, stir for 1 hour; filter to take the precipitate, wash the product with a mixture of 300ml acetone and 50ml purified water, vacuum Dry to obtain 58.5g intermediate compound of formula (II), yield 82.7%;

中间体式(II)结构的化合物经1H NMR(400MHz,CDCl3)检测,结果同实施例1。The intermediate compound of formula (II) was detected by 1 H NMR (400 MHz, CDCl 3 ), and the result was the same as that in Example 1.

实施例4Example 4

如实施例1所述的头孢西丁的制备方法,不同之处在于:The preparation method of cefoxitin as described in embodiment 1, difference is:

步骤(3)中,将60g按照实施例1步骤(2)制得的中间体式(II)结构的化合物加入到900ml二氯甲烷与200ml甲醇的混合溶液中,降温至-40℃加入对甲基苯磺酸18.5ml,降温至-85℃,然后加入130g 30wt%甲醇钠的甲醇溶液和23.2g次氯酸叔丁酯进行甲氧化反应,反应完成后加入30g焦亚硫酸钠和36ml冰醋酸,然后加入500ml水,调节体系pH值6~7,静置分层。水相加入8g活性炭搅拌脱色20分钟,过滤,用水300ml洗涤,合并滤液,用10wt%的盐酸调节料液至pH=2,式(I)结构的化合物析出,降温至0~5℃搅拌1小时;过滤取沉淀,用200ml纯化水和12ml乙酸乙酯的混合液洗涤产品,经真空干燥得到51.7g式(I)结构的化合物,即头孢西丁,收率84.6%。In step (3), 60 g of the compound of the intermediate formula (II) structure prepared according to step (2) of Example 1 was added to a mixed solution of 900 ml of dichloromethane and 200 ml of methanol, and the temperature was lowered to -40 °C and p-methyl 18.5ml of benzenesulfonic acid, cooled to -85°C, then added 130g of 30wt% methanol solution of sodium methoxide and 23.2g of tert-butyl hypochlorite for methoxidation reaction, added 30g of sodium pyrosulfite and 36ml of glacial acetic acid after the reaction was completed, and then added 500ml of water, adjust the pH value of the system to 6-7, and let it stand for stratification. Add 8g of activated carbon to the water phase and stir for 20 minutes to decolorize, filter, wash with 300ml of water, combine the filtrates, adjust the feed solution to pH=2 with 10wt% hydrochloric acid, the compound of the formula (I) structure is precipitated, cool to 0-5°C and stir for 1 hour Get precipitate by filtration, wash product with the mixed solution of 200ml purified water and 12ml ethyl acetate, obtain the compound of 51.7g formula (I) structure through vacuum drying, i.e. cefoxitin, yield 84.6%.

头孢西丁经1H NMR(400MHz,CDCl3)检测,结果同实施例1。Cefoxitin was detected by 1 H NMR (400 MHz, CDCl 3 ), and the result was the same as that in Example 1.

实施例5Example 5

如实施例4所述的头孢西丁的制备方法,不同之处在于:The preparation method of cefoxitin as described in embodiment 4, difference is:

将60g按照实施例3步骤(2)制得的中间体式(II)结构的化合物加入到600ml二氯甲烷、80ml四氢呋喃与100ml甲醇的混合溶液中,降温至-15℃加入11.0ml甲磺酸,降温至-85℃,然后加入140g 30wt%甲醇钠的甲醇溶液和24.5g次氯酸叔丁酯进行甲氧化反应,反应完成后加入30g焦亚硫酸钠和36ml冰醋酸,然后加入500ml水,调节体系pH值6~7,静置分层。水相加入8g活性炭搅拌脱色20分钟,过滤,用水300ml洗涤,合并滤液,用10wt%的盐酸调节料液至pH=2,式(I)结构的化合物析出,降温至0~5℃搅拌1小时;过滤取沉淀,用200ml纯化水和12ml乙酸乙酯的混合液洗涤产品,经真空干燥得到50.9g式(I)结构的化合物,即头孢西丁,收率83.3%。Add 60 g of the compound of the intermediate formula (II) obtained according to step (2) of Example 3 to a mixed solution of 600 ml of dichloromethane, 80 ml of tetrahydrofuran and 100 ml of methanol, cool down to -15°C and add 11.0 ml of methanesulfonic acid, Cool down to -85°C, then add 140g of 30wt% methanol solution of sodium methoxide and 24.5g of tert-butyl hypochlorite for methoxidation reaction, add 30g of sodium metabisulfite and 36ml of glacial acetic acid after the reaction is completed, and then add 500ml of water to adjust the pH of the system The value is 6-7, standing for layering. Add 8g of activated carbon to the water phase and stir for 20 minutes to decolorize, filter, wash with 300ml of water, combine the filtrates, adjust the feed solution to pH=2 with 10wt% hydrochloric acid, the compound of the formula (I) structure is precipitated, cool to 0-5°C and stir for 1 hour Get precipitate by filtration, wash product with the mixed solution of 200ml purified water and 12ml ethyl acetate, obtain the compound of 50.9g formula (I) structure through vacuum drying, i.e. cefoxitin, yield 83.3%.

头孢西丁经1H NMR(400MHz,CDCl3)检测,结果同实施例1。Cefoxitin was detected by 1 H NMR (400 MHz, CDCl 3 ), and the result was the same as that in Example 1.

Claims (10)

1. the preparation method of a cefoxitin is characterized in that, synthetic route is following:
Figure FDA0000156683140000011
In the formula, M +Be Na +Or Et 3NH +, DBED is N, N '-dibenzyl-ethylenediamin diacetate, CSI are Sulfuryl chloride isocyanate;
Comprise the steps:
(1) in the compound water solution of formula (IV) structure; Add organic solvent A, temperature control adds N, N '-dibenzyl-ethylenediamin diacetate or N for 10 ℃~50 ℃; The aqueous solution of N '-dibenzyl-ethylenediamin diacetate; The compound of midbody formula (III) structure is separated out, and is cooled to 0~10 ℃, filters the compound that obtains midbody formula (III) structure;
Organic solvent A is: one of methylene dichloride, chloroform or arbitrarily than combination;
The compound of midbody formula (III) structure that (2) step (1) is made joins in acetone or the THF; Temperature control-65 ℃~-20 ℃; Add Sulfuryl chloride isocyanate and carry out the carbamylation reaction, add entry or acid then and be warming up to-10 ℃~20 ℃ and be hydrolyzed; Add ETHYLE ACETATE after hydrolysis is accomplished, filter and remove benzyl star hydrochloride, filtrate with after the sodium chloride aqueous solution washing; Organic phase adds sodium bicarbonate aqueous solution product is extracted into water; Add the chlorination sodium salt after the decolouring and analyse, cross the leaching deposition, get the compound of midbody formula (II) structure;
The compound of midbody formula (II) structure that (3) step (2) is made adds in the organic solvent B; Under-80~0 ℃ condition; Add organic acid and make its supersaturated solution that forms the de-methoxy cefoxitin acid, the methanol solution and the t-butyl hypochlorate of temperature control-95~-70 ℃ adding sodium methylate carry out the methoxy reaction then; After the methoxy reaction finished, adding Sodium Pyrosulfite and acetic acid neutralization added the water extraction, and water is crossed the leaching deposition through acid out, gets formula (I) compound, i.e. cefoxitin;
Organic solvent B be selected from one of methylene dichloride, THF, methyl alcohol or arbitrarily than combination.
2. preparation method as claimed in claim 1 is characterized in that, the compound of said step (1) Chinese style (IV) structure is deacetylate Glaxo) or deacetylate cefoxitin triethylamine salt.
3. preparation method as claimed in claim 1 is characterized in that, the compound and the N of said step (1) Chinese style (IV) structure, and the reaction mol ratio of N '-dibenzyl-ethylenediamin diacetate is 1: (0.5~1); Preferably, the organic solvent A in the said step (1) is: methylene dichloride or chloroform.
4. preparation method as claimed in claim 1 is characterized in that, the compound mol ratio of Sulfuryl chloride isocyanate and midbody formula (III) structure is (1~3) in the said step (2): 1.
5. preparation method as claimed in claim 1 is characterized in that, the acid in the said step (2) is hydrochloric acid or sulfuric acid.
6. preparation method as claimed in claim 1 is characterized in that, in the said step (3), it is-80~0 ℃ that organic acid adds temperature; Preferably, organic solvent B is methylene dichloride or THF, perhaps methylene dichloride, THF and the combination of methyl alcohol with any ratio.
7. preparation method as claimed in claim 1 is characterized in that, in the said step (3), organic acid be one of formic acid, trifluoroacetic acid, fluoroboric acid, methylsulfonic acid, p-methyl benzenesulfonic acid or arbitrarily than combination; Preferred organic acid is methylsulfonic acid or p-methyl benzenesulfonic acid.
8. preparation method as claimed in claim 1 is characterized in that, in the said step (3), the mol ratio of the compound of organic acid and midbody formula (II) structure is (1~2): 1.
9. preparation method as claimed in claim 1 is characterized in that, in the said step (3), the methoxy temperature of reaction is-95~-80 ℃, and the compound mol ratio of sodium methylate and midbody formula (II) structure is (3~8): 1; The compound mol ratio of t-butyl hypochlorate and midbody formula (II) structure is (1~3): 1.
10. preparation method as claimed in claim 1 is characterized in that, comprises the steps:
(1) in the aqueous solution 1000ml that contains deacetylate Glaxo) 100~120g, adds 200ml methylene dichloride (organic solvent A); And then temperature control adds 50~80g N for 20 ℃~40 ℃; The solution that N '-dibenzyl-ethylenediamin diacetate and 800ml water are made into, the compound of midbody formula (III) structure is separated out, and is cooled to 0~10 ℃; Cross the leaching deposition, obtain the compound of midbody formula (III) structure;
The compound of midbody formula (III) structure that (2) step (1) is made joins in the 1000ml acetone, is cooled to-50 ℃~-20 ℃ and drips Sulfuryl chloride isocyanate 35~60ml, carries out the carbamylation reaction; HPLC adds 198ml water after detecting carbamylation reaction completion, is warming up to-10~10 ℃ and is hydrolyzed; Add ETHYLE ACETATE 1980ml after hydrolysis is accomplished, filter and remove benzyl star hydrochloride, filtrating is washed with sodium chloride aqueous solution; Layering, organic phase add sodium bicarbonate aqueous solution product are extracted into water, and water adds activated carbon decolorizing then; Filter, filtrating adds the sodium-chlor of 200g to be saltoutd, and the compound of midbody formula (II) structure is separated out; Stir filtration in 1 hour, obtain the compound of midbody formula (II) structure;
The compound of midbody formula (II) structure that (3) step (2) is made joins in the 680ml THF, is cooled to-50~-10 ℃, adds 16.0~21.4ml methylsulfonic acid; Be cooled to-95~-80 ℃, the methanol solution and the 24.25~30.75g t-butyl hypochlorate that add 160~220g 30wt% sodium methylate then carry out the methoxy reaction, add 51g Sodium Pyrosulfite and 61.5ml Glacial acetic acid min. 99.5 after reaction is accomplished; Add activated carbon decolorizing then, add 850ml water again, regulate pH=2 with hydrochloric acid; Be cooled to 0~10 ℃; Cross the leaching deposition, obtain the compound of formula (I) structure, i.e. cefoxitin.
CN2012101220349A 2012-04-24 2012-04-24 Preparation method of cefoxitin Pending CN102633819A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2012101220349A CN102633819A (en) 2012-04-24 2012-04-24 Preparation method of cefoxitin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2012101220349A CN102633819A (en) 2012-04-24 2012-04-24 Preparation method of cefoxitin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410529255.7A Division CN104230956B (en) 2012-04-24 2012-04-24 A kind of preparation method of cefoxitin

Publications (1)

Publication Number Publication Date
CN102633819A true CN102633819A (en) 2012-08-15

Family

ID=46618412

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2012101220349A Pending CN102633819A (en) 2012-04-24 2012-04-24 Preparation method of cefoxitin

Country Status (1)

Country Link
CN (1) CN102633819A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104072521A (en) * 2014-06-27 2014-10-01 广东省石油化工研究院 Preparation method for cefoxitin acid
CN105254650A (en) * 2015-11-02 2016-01-20 四川清山绿水实业发展有限公司 Synthesis method of antibacterial drug cefoxitin
CN110283869A (en) * 2019-07-05 2019-09-27 国药集团威奇达药业有限公司 The preparation method of 7-amino-cephalosporanic acid
CN111217836A (en) * 2020-03-20 2020-06-02 侯二美 Preparation method of cefoxitin
CN112094280A (en) * 2020-09-09 2020-12-18 苏州盛达药业有限公司 Preparation method of cefoxitin derivative
CN112851693A (en) * 2021-01-22 2021-05-28 华北制药河北华民药业有限责任公司 Preparation method of cefoxitin acid

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4041029A (en) * 1971-11-29 1977-08-09 Merck & Co., Inc. Acylimine cephalosporins
US4297488A (en) * 1970-06-16 1981-10-27 Merck & Co., Inc. 7-α-Methoxy cephalosporins
WO2004083217A1 (en) * 2003-03-20 2004-09-30 Orchid Chemicals & Pharmaceuticals Ltd An improved process for the preparation of cefoxitin
EP1748049A2 (en) * 2005-07-27 2007-01-31 ACS DOBFAR S.p.A. Process for preparing cefoxitin
CN101235045A (en) * 2008-02-26 2008-08-06 芦红代 Method for preparing cefoxitin sodium
CN101555252A (en) * 2009-05-21 2009-10-14 苏州致君万庆药业有限公司 Synthetic method of antibiotic cefoxitin
CN101613361A (en) * 2009-08-07 2009-12-30 哈药集团制药总厂 Preparing cefoxitin sodium

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4297488A (en) * 1970-06-16 1981-10-27 Merck & Co., Inc. 7-α-Methoxy cephalosporins
US4041029A (en) * 1971-11-29 1977-08-09 Merck & Co., Inc. Acylimine cephalosporins
WO2004083217A1 (en) * 2003-03-20 2004-09-30 Orchid Chemicals & Pharmaceuticals Ltd An improved process for the preparation of cefoxitin
EP1748049A2 (en) * 2005-07-27 2007-01-31 ACS DOBFAR S.p.A. Process for preparing cefoxitin
CN101235045A (en) * 2008-02-26 2008-08-06 芦红代 Method for preparing cefoxitin sodium
CN101555252A (en) * 2009-05-21 2009-10-14 苏州致君万庆药业有限公司 Synthetic method of antibiotic cefoxitin
CN101613361A (en) * 2009-08-07 2009-12-30 哈药集团制药总厂 Preparing cefoxitin sodium

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104072521A (en) * 2014-06-27 2014-10-01 广东省石油化工研究院 Preparation method for cefoxitin acid
CN105254650A (en) * 2015-11-02 2016-01-20 四川清山绿水实业发展有限公司 Synthesis method of antibacterial drug cefoxitin
CN110283869A (en) * 2019-07-05 2019-09-27 国药集团威奇达药业有限公司 The preparation method of 7-amino-cephalosporanic acid
CN110283869B (en) * 2019-07-05 2021-06-25 国药集团威奇达药业有限公司 Preparation method of 7-aminocephalosporanic acid
CN111217836A (en) * 2020-03-20 2020-06-02 侯二美 Preparation method of cefoxitin
CN112094280A (en) * 2020-09-09 2020-12-18 苏州盛达药业有限公司 Preparation method of cefoxitin derivative
CN112851693A (en) * 2021-01-22 2021-05-28 华北制药河北华民药业有限责任公司 Preparation method of cefoxitin acid
CN112851693B (en) * 2021-01-22 2022-08-16 华北制药河北华民药业有限责任公司 Preparation method of cefoxitin acid

Similar Documents

Publication Publication Date Title
CN102633819A (en) Preparation method of cefoxitin
CN105131017B (en) A kind of preparation method of Method of cefcapene pivoxil hydrochloride
CN101613359A (en) Method for synthesizing cefuroxime sodium
CN104725425A (en) Preparation method for ceftaroline fosamil
CN102659817B (en) Preparation method of cefdinir
CN100516070C (en) The method for preparing 7-amino-3-vinyl cephalosporanic acid
CN110590812A (en) Preparation method of cefminox sodium
CN104230956B (en) A kind of preparation method of cefoxitin
CN103848851B (en) A kind of synthetic method of Method of cefcapene pivoxil hydrochloride
CN105859747A (en) Cefepime dihydrochloride preparation method suitable for industrial production
US4935508A (en) Process for cephem prodrug esters
CN106220648B (en) A kind of synthesis of tertbutyloxycarbonyl Cefcapene diisopropylamine and purification process
CN104610280B (en) A kind of preparation method of cephalothin acid
JP4022070B2 (en) Novel thiazole compound and method for producing the same
CN104892674B (en) Preparation method of ceftaroline fosamil
CN102911186A (en) Ceftizoxime sodium preparation and refining method
CN103044416A (en) Synthetic method of Carumonam sodium
CN108033971B (en) Method for synthesizing cefcapene pivoxil hydrochloride
CN101486720B (en) Method for synthesizing cefodizime sodium compound
CN100357294C (en) Novel crystal of 7- 2-(2-aminothiazole-4-yl)-2-hydroxyiminoa cetamido-3-vinyl-3-cephem-4-carboxylic acid (syn isomer) and method for preparation thereof
US20050032771A1 (en) Process for the preparation of cefixime via alkyl-or aryl-sulfonates
CN101550148B (en) Refining method of Cefpodoxime proxetil compound
CN108299469B (en) Preparation method of cefotiam hydrochloride
CN113185538B (en) Preparation method of cefpodoxime acid
CN120309632A (en) A preparation method of cefpodoxime axetil

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120815